Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO 2019 Congress

Janssen Pharmaceutical Companies of Johnson & Johnson - Integrating precision medicine: Are we ready for a paradigm shift in advanced urothelial carcinoma?

What is today’s understanding of the molecular landscape of advanced urothelial carcinoma?

Date

27 Sep 2019

Session

Janssen Pharmaceutical Companies of Johnson & Johnson - Integrating precision medicine: Are we ready for a paradigm shift in advanced urothelial carcinoma?

Presenters

Eva Comperat

Authors

E. Comperat

Author affiliations

  • Ap-hp Service Of Pathology Tenon Hospital, Sorbonne University, GRC n°5, ONCOTYPE-URO, 75020 - PARIS/FR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Login

Resources from the same session

Introduction: Welcome to the future?

Presenter: Joaquim Bellmunt

Session: Janssen Pharmaceutical Companies of Johnson & Johnson - Integrating precision medicine: Are we ready for a paradigm shift in advanced urothelial carcinoma?

Resources:

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.